Duyuru • Apr 08
InnoCan Pharma Corporation announced that it has received $0.2 million in funding On April 6, 2026,InnoCan Pharma Corporation closed the transaction. The company has raised $200,000 in the transaction. Duyuru • Apr 02
InnoCan Pharma Corporation announced that it expects to receive $0.2 million in funding InnoCan Pharma Corporation announced that will receive gross proceeds of $200,000 in a round of funding on March 31, 2026. The transaction includes participation from new lender Tamar Innovest Limited. The company will issue non convertible debt in the transaction. The notes bear a fixed interest rate of 10% per annum and will be issued at par. The company will pay the accrued interest on a yearly period. The notes will will mature at the earlier of: (i) 12 months from the date of issuance; and (ii) the completion of the Company's previously announced proposed public offering in the United States pursuant to its registration statement on F-1 filed with the U.S. Securities and Exchange Commission, as amended. The transaction is expected close on April 1, 2026. Reported Earnings • Mar 31
Full year 2025 earnings released: US$0.25 loss per share (vs US$0.43 loss in FY 2024) Full year 2025 results: US$0.25 loss per share (improved from US$0.43 loss in FY 2024). Revenue: US$26.6m (down 9.6% from FY 2024). Net loss: US$1.12m (loss narrowed 39% from FY 2024). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Duyuru • Mar 17
InnoCan Pharma Corporation announced that it has received $0.45 million in funding On March 16, 2026, InnoCan Pharma Corporation, closed the transaction. The company has received $450,000 in funding. Duyuru • Mar 12
InnoCan Pharma Corporation announced that it expects to receive $0.45 million in funding InnoCan Pharma Corporation announced that will receive gross proceeds of $450,000 in a round of funding on March 11, 2026. The transaction includes participation from new lender Tamar Innovest Limited. The notes bear a fixed interest rate of 10% per annum and will be issued at par. The company will pay the accrued interest on a yearly period. The company issues non convertible debt in the transaction. The company will issue pursuant to its registration statement on F-1 filed with the U.S. securities and exchange commission. The transaction is expected close on March 12, 2026. New Risk • Jan 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risk Market cap is less than US$100m (CA$33.1m market cap, or US$24.5m). New Risk • Dec 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risk Market cap is less than US$100m (CA$33.7m market cap, or US$24.7m). Reported Earnings • Nov 29
Third quarter 2025 earnings released: US$0.43 loss per share (vs US$0.067 loss in 3Q 2024) Third quarter 2025 results: US$0.43 loss per share (further deteriorated from US$0.067 loss in 3Q 2024). Revenue: US$6.82m (down 21% from 3Q 2024). Net loss: US$1.95m (loss widened US$1.66m from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. New Risk • Sep 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 37% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$78.5m market cap, or US$56.7m). Reported Earnings • Aug 28
Second quarter 2025 earnings released: US$0.002 loss per share (vs US$0.001 profit in 2Q 2024) Second quarter 2025 results: US$0.002 loss per share (down from US$0.001 profit in 2Q 2024). Revenue: US$7.01m (down 19% from 2Q 2024). Net loss: US$590.0k (down 275% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Duyuru • Aug 25
Innocan Pharma Corporation to Showcase a Poster Outlining Key Data on LPT-CBD Pharmacokinetics and Efficacy Along with the Recently Published Narrative Review Innocan Pharma Corporation announced that during the PAINWeek conference 2025, it will showcase a poster outlining key data on LPT-CBD pharmacokinetics and efficacy along with the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI:). PAINWeek is the premier US national conference on pain management, taking place this year in Las Vegas, Nevada, from September 2-5, 2025. The poster will be showcased during the scientific poster reception on September 4 (Poster #29), presented by Joseph V. Pergolizzi, Jr., MD, MBA, NEMA Research, a key member of Innocan's advisory board. PAINWeek is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by preclinical animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability-offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. Unlike over-the-counter CBD oils and supplements, Innocan's LPT-CBD is being developed as a pharmaceutical-grade, controlled-release injectable designed to deliver consistent therapeutic levels of CBD. The endocannabinoid system is a validated target in pain modulation, and Innocan's long-acting synthetic CBD platform may represent a breakthrough approach to harnessing this pathway. With opioid dependency remaining a global health crisis, LPT-CBD have the potential to emerge as a safe, effective non-opioid therapy for chronic pain management. LPT-CBD will be presented at the PAINWeek conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. Duyuru • Jun 21
Innocan Pharma Corporation Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference Innocan Pharma Corporation announced that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability-offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of non-opioid chronic pain management solutions. New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$52.6m market cap, or US$38.4m). Reported Earnings • May 29
First quarter 2025 earnings released: US$0.002 loss per share (vs US$0.007 loss in 1Q 2024) First quarter 2025 results: US$0.002 loss per share (improved from US$0.007 loss in 1Q 2024). Revenue: US$7.80m (up 15% from 1Q 2024). Net loss: US$582.0k (loss narrowed 67% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Duyuru • May 09
InnoCan Pharma Corporation, Annual General Meeting, Jun 26, 2025 InnoCan Pharma Corporation, Annual General Meeting, Jun 26, 2025. Duyuru • May 07
Innocan Pharma Corporation First Granted Patent in Mexico for Its Topical Pain Relief Innocan Pharma Corporation announced that the Mexican patent office has issued a notice of allowance for the Company's patent application covering its proprietary topical pain-relief technology. This patent covers a formulation comprising the unique blending of cannabidiol with minerals to deliver fast-acting, targeted pain relief. Clinical studies have demonstrated noticeable pain reduction within 20 minutes of application. The approval of this patent represents a major milestone in Innocan's mission to advance next-generation topical therapeutic solutions. The Mexican allowance adds to previously granted counterpart patents in the United States, Russia, and Ukraine, and complements a growing portfolio of pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets. Innocan Pharma intends to continue expanding its intellectual property portfolio in other key territories worldwide, reinforcing its leadership in cannabidiol-based wellness innovation. Duyuru • Apr 16
InnoCan Pharma Corporation announced that it has received CAD 0.214839 million in funding On April 15, 2025, InnoCan Pharma Corporation closed the transaction. The company issued 1,193,551 units at an issue price of CAD 0.18 per unit for gross proceeds of CAD 214,839.18. Reported Earnings • Apr 01
Full year 2024 earnings released: US$0.007 loss per share (vs US$0.018 loss in FY 2023) Full year 2024 results: US$0.007 loss per share (improved from US$0.018 loss in FY 2023). Revenue: US$29.4m (up 116% from FY 2023). Net loss: US$1.83m (loss narrowed 61% from FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Duyuru • Mar 08
InnoCan Pharma Corporation announced that it has received $1 million in funding On March 7, 2025, InnoCan Pharma Corporation closed the transaction. Duyuru • Feb 28
InnoCan Pharma Corporation announced that it expects to receive $1 million in funding InnoCan Pharma Corporation announced a private placement to issue one secured convertible debenture and 5,555,555 common share purchase warrants for gross proceeds of $1,000,000 on February 27, 2025. The transaction will include participation from returning investor Tamar Innovest Ltd. The Debenture matures two years from the date of issuance, will bear interest at the rate of 10% per annum and is convertible into common shares of prior to the Maturity Date at a price of $0.21 per share Each Warrant is exercisable into one Common Share at a price of CAD$0.26 ($0.18141) for a period of four years from the date of issuance. The Offering is expected to close on or around March 6, 2025. The securities issued to Canadian subscribers in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. Duyuru • Feb 11
Innocan Pharma Corporation Announces Successful Outcome from the Compassionative Treatment with Its Innovative Liposomal Cbd Injection (Lpt-Cbd) Innocan Pharma Corporation announced the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD injection (LPT-CBD). Innocan's innovative therapy provided quick and sustained pain relief, significantly improving mobility in an elderly female donkey suffering from osteoarthritis. Ariel, a 35-year-old elderly female donkey residing at a rescue farm, had endured years of carrying excessive weight, leading to debilitating osteoarthritis across multiple joints. The chronic pain severely limited her mobility, affecting her overall well-being. As an act of compassionate therapy, Ariel was administered a single LPT-CBD injection. Positive effects were observed, and Ariel mobility was improved for several weeks. Due to the remarkable success of the treatment, she was given a second LPT-CBD dose, which demonstrated continued improvement in her condition. LPT-CBD is a proprietary innovative injectable liposomal formulation designed for the sustained release of synthetic CBD, targeting the treatment of chronic pain in both human and veterinary patients. New Risk • Feb 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$46.4m market cap, or US$31.9m). Duyuru • Jan 02
InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding On December 31, 2024 InnoCan Pharma Corporation closed the transaction and issued 3,177,223 Units at a price of CAD 0.20 per Unit for aggregate gross proceeds of CAD 635,444.60. The Company paid an arm's length finder a cash fee of CAD 13,500 and issued to the finder 67,500 warrants attributable to investors introduced to the Company by the finder within 3 months following such introduction. Each Finder Warrant entitles the Finder to purchase one Common Share at an exercise price of CAD 0.28 for a period of four (4) years from the date of issuance. Duyuru • Dec 20
InnoCan Pharma Corporation announced that it expects to receive CAD 0.7 million in funding Innocan Pharma Corporation announced a non brokered private placement of up to 3,500,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of CAD 700,000 on December 19, 2024. Each Unit will be comprised of one common share and one common share purchase warrant. ach Warrant will entitle the holder thereof to purchase one Common Share at a price of CAD 0.28 for a period of four years from the date of issuance. The securities issued to Canadian subscribers in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws Reported Earnings • Nov 21
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.008 loss in 3Q 2023) Third quarter 2024 results: US$0.001 loss per share (improved from US$0.008 loss in 3Q 2023). Revenue: US$8.62m (up 111% from 3Q 2023). Net loss: US$290.0k (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Duyuru • Oct 12
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs Innocan Pharma Corporation announced promising results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. LPT-CBD, a monthly injectable treatment, has the potential to have superior bioavailability by avoiding first-pass liver metabolism. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased, clearly noticeable well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years respectively after their owners reported significant improvement in quality of life when receiving the treatment in addition to conventional treatments. Previous pilot studies by Innocan have shown similarly encouraging outcomes. Recent Insider Transactions Derivative • Sep 29
CEO & Director exercised options to buy CA$53k worth of stock. On the 20th of September, Iris Bincovich exercised options to buy 222k shares at a strike price of around CA$0.24, costing a total of CA$53k. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. Since March 2024, Iris' direct individual holding has increased from 4.94m shares to 5.16m. Company insiders have collectively bought CA$458k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Sep 23
CEO & Director exercised options to buy CA$53k worth of stock. On the 16th of September, Iris Bincovich exercised options to buy 222k shares at a strike price of around CA$0.24, costing a total of CA$53k. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. Since March 2024, Iris has owned 4.94m shares directly. Company insiders have collectively bought CA$229k more than they sold, via options and on-market transactions, in the last 12 months. Duyuru • Aug 30
InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding On August 29, 2024, InnoCan Pharma Corporation closed the transaction. The company issued 5,025,725 units of the Company at a price of CAD 0.22 per Unit for gross proceeds up to CAD 1,105,659.50 Duyuru • Aug 23
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of up to 4,000,000 units of the Company at a price of CAD 0.22 per Unit for gross proceeds up to CAD 880,000 on August 22, 2024.The Offering is expected to close on or around August 29, 2024. Each Unit will be comprised of one common share in the capital of the Company; and one common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at a price of CAD 0.32 for a period of four years from the date of issuance. Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.001 (up from US$0.002 loss in 2Q 2023). Revenue: US$8.64m (up 177% from 2Q 2023). Net income: US$337.0k (up US$857.0k from 2Q 2023). Profit margin: 3.9% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Duyuru • Jul 27
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center Innocan Pharma Corporation announced that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. Reported Earnings • May 28
First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023) First quarter 2024 results: US$0.007 loss per share (further deteriorated from US$0.005 loss in 1Q 2023). Revenue: US$6.77m (up 334% from 1Q 2023). Net loss: US$1.77m (loss widened 39% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Duyuru • May 10
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey Innocan Pharma Corporation announced the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan's innovative therapy provided immediate noticeable pain relief and improved mobility. Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri's condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her. As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed. Reported Earnings • Apr 02
Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022) Full year 2023 results: US$0.018 loss per share (further deteriorated from US$0.015 loss in FY 2022). Revenue: US$13.7m (up 434% from FY 2022). Net loss: US$4.70m (loss widened 25% from FY 2022). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Mar 15
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding On March 14, 2024, InnoCan Pharma Corporation closed the transaction. The company has now issued 7,952,840 units at a price of CAD 0.25 per for the gross proceeds of CAD 1,988,210. Duyuru • Mar 09
InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024 InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024. Agenda: Annual General Special Meeting. Duyuru • Mar 06
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of up to 12,000,000 units at a price of CAD 0.25 per unit for gross proceeds up to CAD 3,000,000 on March 5, 2024. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.32 for a period of four years from the date of issuance. The offering is expected to close on or around March 13, 2024. The securities issued to Canadian subscribers in connection with the offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. Reported Earnings • Nov 30
Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022) Third quarter 2023 results: US$0.008 loss per share (further deteriorated from US$0.001 loss in 3Q 2022). Revenue: US$4.08m (up 445% from 3Q 2022). Net loss: US$2.03m (loss widened US$1.86m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Duyuru • Oct 21
InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding On October 20, 2023, InnoCan Pharma Corporation closed the transaction. The company issued 4,005,408 units at a price of CAD 0.3 per unit for the gross proceeds of CAD 1,201,622.4? in its final tranche. In total, the company issued an aggregate of 5,425,608 units under the offering for aggregate gross proceeds of CAD 1,627,682.40. The company also paid the Agent a corporate finance advisory fee consisting of 122,500 Units, CAD 27,700 in cash and 92,330 Broker Warrants. Duyuru • Sep 22
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding InnoCan Pharma Corporation announced that it has entered into an agreement with Research Capital Corp. as the sole agent and sole bookrunner on a best efforts agency basis of up to 10,000,000 units of the company at a price of CAD 0.3 per unit for the aggregate gross proceeds of CAD 3 million on September 21, 2023. Each unit shall comprise one common share of the company and one common share purchase warrant of the company. Each warrant shall entitle the holder thereof to purchase one common share at an exercise price of CAD 0.36 for a period of 36 months from closing. The company will grant the agent an option to increase the size of the offering by up to 15% of the number of units by giving written notice of the exercise of the agent's option, or a part thereof, to the company at any time up to 48 hours prior to closing of the offering. The transaction is expected to close on October 10, 2023. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the Canadian Securities Exchange. The company has agreed to pay the agent a cash commission equal to 8% of the gross proceeds. The company will also pay the agent a corporate finance fee based on the aggregate gross proceeds of the offering, which will be satisfied by the issuance of units at the same offering price and on the same terms as those issued under the offering. Duyuru • Sep 16
InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board InnoCan Pharma Corporation announced the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications. Dr. Pergolizzi has extensive academic, clinical, and business achievements related to his lifelong interest in advancing medical science and the practice of modern global healthcare. He has gained a strong reputation as an experienced, results-oriented C-level leader with a particular focus on new companies. He has held various C-level positions in private and public companies. He can leverage his significant medical expertise, regulatory experience, and business skills to build a strong track record of success in many fields in the healthcare industry. Dr. Pergolizzi is a Senior Partner at Naples Anesthesia and Pain Associates and serves as the Chief Operating Officer at NEMA Research Inc. He is a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a Consultant to the National Pain Foundation Board of Directors. Dr. Pergolizzi is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He formerly served as a part-time adjunct assistant professor in the Department of Medicine at the Johns Hopkins University School of Medicine. Dr. Pergolizzi has authored over 400 peer-reviewed articles and has been involved in groundbreaking research on topics such as opioid-induced constipation, cardiotoxicity due to cocaine, and the effects of illicitly manufactured fentanyl. His research has been funded by the NIDA/NIH, and he has received numerous accolades, including the Patients Choice Award, Compassionate Doctor Recognition Award, and the Leading Physicians of the World by the IACHP. Reported Earnings • Aug 25
Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022) Second quarter 2023 results: US$0.002 loss per share (improved from US$0.007 loss in 2Q 2022). Revenue: US$3.12m (up US$2.71m from 2Q 2022). Net loss: US$520.0k (loss narrowed 70% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 09
InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding On August 8, 2023, InnoCan Pharma Corporation closed the transaction. New Risk • Aug 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (CA$61.2m market cap, or US$45.7m). Duyuru • Aug 05
InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding InnoCan Pharma Corporation announced a non-brokered private placement of 8,409,735 units at a price of CAD 0.23 per unit for a gross proceeds of CAD 1,934,239.05 on August 4, 2023. Each unit comprises of one common share, one and half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.29 for a period of three years from the date of issuance. Each class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.40 for a period of five years from the date of issuance. The security issued in the transaction are subject to hold period of four month. New Risk • Jul 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Revenue is less than US$5m (US$3.9m revenue). Market cap is less than US$100m (CA$55.2m market cap, or US$41.8m). Duyuru • Jul 26
InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding InnoCan Pharma Corporation announced that it has entered into a non-brokered private placement of 17,220,000 units at a price of CAD 0.23 per unit for gross proceeds of CAD 3,960,600 on July 25, 2023. Each unit consists of one common share and one half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each Class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.29 for a period of three years from the date of issuance. Each Class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.40 for a period of five years from the date of issuance. The securities issued in connection with the Offering will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws. The transaction is expected to closing on July 20, 2023. Duyuru • Jun 15
Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology InnoCan Pharma Corporation has announced the filing of its most recent patent application to the United States Patent and Trademark Office (USPTO). This move is in line with the Company's ongoing strategy to expand the breadth of its distinctive combined Cannabis and Magnesium topical pain-relief technology. This latest continuation patent application encapsulates additional aspects of the Company's combined Magnesium and Cannabis-based solution, explicitly crafted for pain and itching alleviation. The patent application reflects the broad spectrum of Cannabinoids and variable dosage, underlining the promising potential of this novel technology. Innocan is committed to broadening its cannabis-based intellectual property portfolio further and intends to continue filing additional patent applications with the USPTO as well as other global patent offices. This innovative company continues to position itself at the forefront of novel cannabis-based therapeutic solutions. Reported Earnings • Jun 02
First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022) First quarter 2023 results: US$0.005 loss per share (further deteriorated from US$0.003 loss in 1Q 2022). Revenue: US$1.56m (up US$1.30m from 1Q 2022). Net loss: US$1.27m (loss widened 95% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Duyuru • May 09
InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial Innocan Pharma Corporation announced the successful treatment of Billy, a 4-year-old neutered male goat, with a liposomal-CBD injection in a pre-clinical trial. The innovative therapy provided much-needed relief to the animal, born with neurological deficits and scoliosis, resulting in hind-limb paralysis and fore-limb deformity. Scientific research indicates that the success of a pre-clinical trial on large mammals (such as goats) generally infers increased bio-feasibility in similar rates amongst humans. Billy was adapted to move around with a wheelchair, but as his size and weight increased, his scoliosis worsened, and his activity decreased substantially. Despite being administered non-steroidal anti-inflammatory drugs, the goat's pain persisted, and he was unable to move on his wheelchair. As an act of compassion therapy, Billy was administered a lipos anomalies-CBD injection on top of the drugs he was already taking. The results were almost immediate, with the goat becoming active and playing as he used to do over a year ago. The improvement in Billy's activity lasted for almost 4 weeks. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. Reported Earnings • Apr 02
Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021) Full year 2022 results: US$0.015 loss per share (improved from US$0.045 loss in FY 2021). Revenue: US$2.56m (up US$2.36m from FY 2021). Net loss: US$3.76m (loss narrowed 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 17
InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding InnoCan Pharma Corporation announced that it has entered into a non-brokered private placement of 1,982,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 495,500 on February 16, 2023. Each unit consists of one common share and one half of one class A common share purchase warrant and one half of one class B common share purchase warrant. Each Class A warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.31 for a period of two years from the date of issuance. Each Class B warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.44 for a period of three years from the date of issuance. All common shares and warrants issued pursuant to the offering will be subject to a four-month statutory hold period commencing from the closing date under applicable securities laws. Reported Earnings • Nov 29
Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021) Third quarter 2022 results: US$0.001 loss per share (improved from US$0.016 loss in 3Q 2021). Revenue: US$749.0k (up US$695.0k from 3Q 2021). Net loss: US$168.0k (loss narrowed 95% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Nov 19
Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser Innocan Pharma Corporation announced the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Givi Topchishvili will join the advisory team to support Innocan's goals to expand its distribution and licensing activities in the US. Givi Topchishvili is a serial entrepreneur, investor, and author, with 30 years of expertise in business development and market entry in Europe, Asia, and the US. He has founded and led to a successful exit multiple companies in the media, IT, healthcare, business advisory and marketing space. He has extensive experience in business performance transformation, venture capital, due diligence and post- merger integration aligned with emerging markets strategy. Givi Topchishvili follows the key principle of building trustworthy partnerships and he is always focused on the understanding of a client's business challenges and goals on multiple levels. He has created efficient roadmaps leading companies to a transformational change, corporate development, building effective product and channel strategies, and in certain cases, executing successful M&A and post- merger integrations. As a published author, he wrote a number of books on business strategy, including "Marketing in the New Millennium - Models for Success" and "The Science of Winning in Investments, Management, and Marketing." Holds a Ph.D. in Physical Chemistry and is active in a number of charitable organizations and business societies. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Peter Bloch was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Sep 10
Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy Innocan Pharma Corporation announced additional positive results in a new preclinical trial involving a dog with refractory (drug- resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections. The dog in the study is a 4-year-old intact male border collie dog with a body weight of 22 kg, suffering from refractory idiopathic (drug-resistant) epilepsy. The dog was treated with three anti-epileptic drugs but was still suffering from seizures several times a month and was hospitalized approximately once a month in order to stop epileptic clusters (frequent seizure events, i.e., every couple of hours) by using intravenous medications. The dog was treated with several injections of Innocan Pharma's LPT (CBD Loaded Liposome Platform) with a 4-week interval between injections. During the several months of the trial, the dog did not require hospitalization. Additionally, since the last LPT injection, the dog did not experience a seizure for a duration of 9.5 weeks. Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizures. It is one of the most common neurological disorders worldwide, affecting people of all ages. Presently, around 50 million patients are living with epilepsy worldwide and about 2.4 million new cases are diagnosed annually. Reported Earnings • Aug 30
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: US$415.0k (up 366% from 2Q 2021). Net loss: US$1.74m (loss widened 67% from 2Q 2021). Duyuru • Aug 18
InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology Innocan Pharma Corporation announced positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform. Six dogs suffering from osteoarthritis and lameness that were treated with oral analgesics but were still experiencing pain were administered a single subcutaneous injection of liposomal CBD in addition to their routine analgesics. CBD concentrations were observed for 6 weeks following the liposomal CBD injection in the dogs' plasma. Owners reported that the dogs' pain and well-being scores were improved for several weeks after the injection. The results show that the LPT technology has the potential to provide additional analgesia in dogs suffering from pain. On August 11, 2022, Innocan reported first results from a study in dogs that showed close to 100% bioavailability of CBD using Innocan's LPT technology, compared to 6.5-20% bioavailability in humans when administered orally. By administering injectable CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and therapeutic levels of CBD in the body. Innocan believes this will create a far more effective and prolonged therapeutic effect. Innocan carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, supporting the viability of Innocan's intention to make CBD available to humans and animals for extended periods upon a single injection. Innocan's unique delivery method allows for the prolonged release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research is conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the Company's technology to deliver cannabinoids to the blood stream in a more effective manner. Duyuru • Aug 06
InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss Innocan Pharma Corporation announced that it has filed a new patent application entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent hair loss and is applied topically to the skin or scalp. This application contributes to Innocan's continued expansion of its health and wellness intellectual property portfolio of 14 patent families. The application will ultimately result in more comprehensive international protection for the Company's intellectual property, including in the United States and the European Union, among other places. The hair loss treatment products market size was valued at almost USD 16 million in 2020 and is projected to grow to more than USD 45 million by 2028, representing a compound annual growth rate of 13.26% between 2021 to 2028. Duyuru • Jul 30
Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms Innocan Pharma Corporation announced that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic symptoms", claiming priority from an earlier US provisional patent application. This application contributes to Innocan's continued expansion of its health and wellness intellectual property portfolio of 14 patent families. The application will ultimately result in more comprehensive international protection for the Company's intellectual property, including in the United States and the European Union, among other places. Diabetes is a condition associated with the body's production or use of insulin, which can have implications for circulation. Innocan's PCT involves a cannabinoid-based composition which can be used to improve circulation and thereby treat ailments associated with diabetes. Duyuru • Jul 07
InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT Innocan Pharma Corporation announced positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections. The results demonstrated that the frequency and the intensity of the dog's epileptic seizures decreased significantly. The dog in the study is Paco, which is a 9 year-old intact male cane corso dog with a body weight of 47 kg. Paco suffered from refractory idiopathic (drug-resistant) epilepsy. Paco was treated with two anti- epileptic drugs but was still suffering from seizures several times a month. Paco was administered several injections of the LPT drug with a 4-week interval between injections. Since the last LPT injection on April 25, 2022, Paco has not suffered from any seizures i.e., over 10 weeks to date. By administering CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long- lasting and significant levels of CBD in the body. Innocan believes this will create a far more effective and continuous therapeutic effect. Innocan carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, validating the viability of Innocan's intention to make CBD available to humans and animals for extended periods upon a single dosage. Innocan's unique delivery method allows for the controlled release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research was conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the Company's technology to deliver cannabinoids to the blood stream in an effective manner. Duyuru • Jun 26
Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management Innocan Pharma Corporation announced successful preclinical trials in dogs with osteoarthritis. A case entailing the clinical condition of Goody, a 8-year-old male mixed-breed dog, who was rescued in a terrible condition after he was found tied up with a very short leash, cachectic and wounded, was published. Goody suffers from severe osteoarthriti in most of his joints, and severe muscle atrophy, mostly surrounding the pelvic limbs. Goody was already treated with joint supplements, non-steroidal anti-inflammatory drugs, and hydrotherapy. The liposomal CBD was administered on top of these treatments. Innocan's Unique Solution: By administering CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long- lasting and significant levels of CBD in the body, which Innocan believes will create a far more effective and continuous therapeutic effect. Innocan carried out a series of experiments of its LPT platform on animals. These experiments have demonstrated initial positive results, validating the viability of Innocan's intention to make CBD available to humans and animals for extended periods upon a single dosage. Innocan's unique delivery method allows for the controlled release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research was conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the Company's technology to deliver cannabinoids to the blood stream in an effective manner. Duyuru • Jun 19
Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment Innocan Pharma Corporation announced that it has filed a new PCT patent application entitled "Compositions for Treatment of Vaginal Atrophy" on June 12, 2022, claiming priority from a US provisional patent. Vaginal atrophy is a condition associated with loss of moisture, thinning, and inflammation of the vaginal walls, which can be associated with decrease in estrogen levels in women, often associated with menopause. This PCT application disclosed compositions which can be used to alleviate vaginal dryness and vaginal atrophy. By filing this PCT application, Innocan is continuing to expand its IP portfolio. Such application will provide Innocan the opportunity to expand its IP protection to diverse countries around the globe. By the end of the PCT period, Innocan will have the possibility to protect its products in marketing site and manufacturing sites. This will include US, EU and other countries where there may be potential business Innocan Pharma positions itself as a source of both potential breakthroughs in skin therapy and further opportunities across a broad spectrum of inflammatory indications with currently unmet medical needs. Reported Earnings • Jun 02
First quarter 2022 earnings released First quarter 2022 results: Net loss: US$651.0k (loss narrowed 87% from 1Q 2021). Board Change • Apr 27
Less than half of directors are independent There are 10 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Director Ralph C. Bossino is the most experienced director on the board, commencing their role in 2019. Independent Director Peter Bloch was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Mar 29
InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform Innocan Pharma Corporation reported the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application and New Drug Application of Innocan's liposomal CBD drug product file following completion of toxicology, pharmacokinetics and efficacy studies. Duyuru • Jun 25
Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study Innocan Pharma Corporation announced that it has completed a cosmetic clinical study of its SHIR® CBD+ ANTI-AGING SLEEPING MASK. The study shows that women who tested the product experienced a reduction in the appearance of their lines and wrinkles by up to 28.8% in as little as 4 weeks. The results were extremely positive and 90.5% of the participants expressed that they would recommend the product to a friend and would like to buy the product. Innocan Pharma's top-notch Research & Development team led by CTO Nir Avram has developed an Anti-Aging skincare line of products. The Anti-Aging complex in the product contains antioxidants with anti-inflammatory properties that are designed to boost collagen and elastin production and reduce photoaging like fine lines and wrinkles. Hydration & anti-wrinkle peptide technology are included in the product to encourage the production of collagen and elastin. The clinical study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal which is an independent, unbiased lab. The findings of the clinical study were consistent with the main principles of ICH GCP, Helsinki declaration and Portuguese legal requirements. Duyuru • Jun 17
Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers InnoCan Pharma Corporation announced that it has completed a cosmetic clinical study of SHIR® CBD Eye Serum on 22 volunteers. Roughly 54% of participants of the study showed a decrease of volume of the participants' eye bags of around 52.18% and with a maximum decrease observed of 90.06%. Statistically significant results in the eye bags' volume were observed 28 days after consecutive application of the investigational product comparatively to the baseline meaning that the product had a positive anti-puffiness effect after 28 days of use. The clinical study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal which is an independent lab. The findings of the clinical study were consistent with the main principles of ICH GCP, Helsinki declaration and Portuguese legal requirements. Duyuru • Jun 15
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment InnoCan Pharma Corporation announced it has filed an international patent application for a novel cannabis-based Vaginal Moisturizer and Lubricant Treatment. The composition comprises cannabinoids and additional agents of a phytoestrogen and hyaluronic acid and may be applied to alleviate vaginal dryness and vaginal atrophy. Vaginal moisturizers and lubricants are applied to help overcome vaginal dryness and solve intercourse difficulties. Vaginal dryness is a common condition faced by women of all ages; however, it is particularly common during and after the menopause transition. It is the result of decreased levels of estrogen, a hormone that keeps the lining of the vagina thick, moisturized, and lubricated. Duyuru • Jun 12
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study InnoCan Pharma Corporation announce that a recent study conducted on mice demonstrated a prolonged release of cannabidiol (CBD) into the animals' bloodstream for at least 7 weeks following local two injections. Innocan believes this result to be extremely encouraging, given the 24-hour maximum CBD presence in the bloodstream when administered through traditional channels. This study was led by Dr. Ahuva Cern, a senior researcher in the lab of Prof. Chezy Berenholz of The Hebrew University of Jerusalem and is based on Innocan's licensed CBD-loaded liposome platform technology ("LPT") for injectable CBD solutions. Duyuru • May 15
Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study Innocan Pharma Corporation announced that a recent study conducted in mice based on Innocan's licensed CBD-loaded liposome platform technology (LPT) for injectable CDB solutions demonstrated a prolonged release of cannabidiol (CBD) into the mice's' bloodstream for at least 50 days following two injections. This study was led by Dr. Ahuva Cern, a senior researcher in the lab of Prof. Barenholz of The Hebrew University of Jerusalem. These results are significant in comparison to oral or inhalation-based intake methods, in which CBD is found to remain in the bloodstream for a maximum-period of 36 hours following a single dose. These results open the door to a wide range of exciting therapeutic possibilities. Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("Yissum"), the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over fifty-five patent families, two of which underlie Doxil®, an FDA-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this Technology on October 7, 2019. Duyuru • Mar 12
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment Innocan Pharma Corporation filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching associated with insect bites, rash, cuts, burns or by exposure to various allergens. Innocan Pharma believes that it's expanding intellectual property portfolio of cannabis-based products to be a source of both potential breakthroughs in skin therapy and for further opportunities across a broad spectrum of inflammatory indications with currently unmet medical needs. Duyuru • Feb 24
InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform InnoCan Pharma Corporation announce the completion of its first full and large-scale commercial production of its SYNONY premium cosmetic line and Relief &Go OTC pain relief spray in the United States and the launch of its US Commercial Website. Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units of its SYNONYTM and Relief & GoTM brands. These production activities will enable the Company to deliver product to the US market, robustly and immediately. Duyuru • Jan 23
Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions Innocan Pharma Corporation announced a successful manufacturing demonstration of liposome platform technology ("LPT") CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem. This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies both of which bring the product closer to the marketplace. This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan's CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection. Is New 90 Day High Low • Jan 16
New 90-day high: CA$0.41 The company is up 41% from its price of CA$0.29 on 16 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 83% over the same period. Duyuru • Jan 15
InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes InnoCan Pharma Corporation announced the successful completion of a large-scale production of exosomes. Innocan's CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3- dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a "guided missile" to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD. Duyuru • Jan 01
InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding InnoCan Pharma Corporation (CNSX:INNO) announced a non-brokered private placement of 10,294,800 units at a price of CAD 0.23 per unit for gross proceeds of CAD 2,367,804 on December 31, 2020. Each unit consists of one share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase one additional common share of the company at an exercise price of CAD 0.35 per share for a period of three years from closing of the transaction. All the securities to be issued in the transaction are subject to a hold period of four-month and a day. The term of the warrants may be accelerated in the event that the company’s shares trade at or above a price of CAD 0.70 per share or for a period of 30 consecutive days. Is New 90 Day High Low • Dec 22
New 90-day high: CA$0.31 The company is up 82% from its price of CA$0.17 on 22 September 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 50% over the same period. Duyuru • Dec 19
InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA InnoCan Pharma Corporation announced the completion of its first commercial production of the Shir premium cosmetic line and Relief & Go topicals in Portugal and announced the commencement of production in the United States, for the first time. The company has completed its first commercial manufacturing run of in Europe/Portugal and will commence a first manufacturing run in North America. In Portugal, InnoCan has now a storage of 35,000 Units of the SHIRTM and Relief & GoTM line and will commence a first manufacturing run in North America, effective immediately to manufacture an initial stock of 40.000 units. These production activities will enable the Company to deliver product to the European and US markets accordingly. Innocan's next step will be to produce additional inventory to service the Company's expansion into the U.S. market as it rapidly expands into retail distribution and scales its online sales. Duyuru • Nov 18
Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases Innocan Pharma Corporation announced the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of Innocan's CBD loaded liposome platform technology ("LPT") in relevant diseases. These studies follow the results of previous studies which demonstrated the prolonged release of Cannabidiol for at least 3 weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem. The original study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Barenholz at the Hebrew University in Jerusalem found significant amounts of CBD in mices' blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats. These results are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration. The results of this study may indicate that Innocan's LPT, with an injection only once or twice a month, may relieve pain or other symptoms when using CBD. These results may open the door for future experiments to prove a lack of toxicity and therapeutic efficacy of this formulation. Innocan Israel has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("Yissum"), the commercial arm of the Hebrew University of Jerusalem in Israel, in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoid) loaded liposomes. The development is led by Prof. Chezy Barenholz, head of the Membrane and Liposome department at the Hebrew University, who invented over 55 patent families, two of which underlie Doxil - the first FDA approved nano-drug aim for cancer treatment. This LPT unique technology platform may be effective for several applications (such as epilepsy, pain relief, and different inflammation and central nervous system disorders). A patent was filed by Innocan Israel on the LPT technology on October 7, 2019. Is New 90 Day High Low • Oct 27
New 90-day high: CA$0.30 The company is up 36% from its price of CA$0.22 on 29 July 2020. The Canadian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period.